Does the media favor MIRM or MRNA?

In the previous week, Moderna had 14 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 21 mentions for Moderna and 7 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Moderna's score of 0.55 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or MIRM?

In the previous week, Roivant Sciences had 9 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 16 mentions for Roivant Sciences and 7 mentions for Mirum Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.12 beat Mirum Pharmaceuticals' score of 0.97 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTX or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat Mirum Pharmaceuticals' score of 0.97 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INSM or MIRM?

In the previous week, Insmed had 12 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for Insmed and 7 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Insmed's score of 0.96 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VTRS or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Viatris' score of 0.54 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mirum Pharmaceuticals (MIRM) Competitors

$117.12 -5.88 (-4.78%)

Closing price 06/30/2026 03:59 PM Eastern

Extended Trading

$116.96 -0.16 (-0.13%)

As of 06/30/2026 07:55 PM Eastern

Compare

MIRM vs. MRNA, ROIV, BNTX, INSM, and VTRS

Should you buy Mirum Pharmaceuticals stock or one of its competitors? MarketBeat compares Mirum Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mirum Pharmaceuticals include Moderna (MRNA), Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Mirum Pharmaceuticals compare to Moderna?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, Moderna had 14 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 21 mentions for Moderna and 7 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Moderna's score of 0.55 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to Moderna's net margin of -143.55%. Mirum Pharmaceuticals' return on equity of -11.28% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Moderna	-143.55%	-26.64%	-19.32%

Mirum Pharmaceuticals has higher earnings, but lower revenue than Moderna. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.70	-$23.36M	-$13.61	N/A
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A

Mirum Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Mirum Pharmaceuticals presently has a consensus target price of $139.80, indicating a potential upside of 19.37%. Moderna has a consensus target price of $37.13, indicating a potential downside of 46.98%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Mirum Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

75.3% of Moderna shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Mirum Pharmaceuticals beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

In the previous week, Roivant Sciences had 9 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 16 mentions for Roivant Sciences and 7 mentions for Mirum Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.12 beat Mirum Pharmaceuticals' score of 0.97 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to Roivant Sciences' net margin of -3,629.19%. Mirum Pharmaceuticals' return on equity of -11.28% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mirum Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,081.71	-$299.77M	-$0.60	N/A
Mirum Pharmaceuticals	$521.31M	13.70	-$23.36M	-$13.61	N/A

Roivant Sciences presently has a consensus target price of $33.59, indicating a potential downside of 5.08%. Mirum Pharmaceuticals has a consensus target price of $139.80, indicating a potential upside of 19.37%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Mirum Pharmaceuticals has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.25	-$1.29B	-$5.88	N/A
Mirum Pharmaceuticals	$521.31M	13.70	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat Mirum Pharmaceuticals' score of 0.97 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a net margin of -44.39% compared to Mirum Pharmaceuticals' net margin of -140.24%. BioNTech's return on equity of -5.30% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

BioNTech presently has a consensus target price of $129.56, indicating a potential upside of 39.24%. Mirum Pharmaceuticals has a consensus target price of $139.80, indicating a potential upside of 19.37%. Given BioNTech's higher possible upside, equities analysts clearly believe BioNTech is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

BioNTech beats Mirum Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, Insmed had 12 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 19 mentions for Insmed and 7 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Insmed's score of 0.96 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed currently has a consensus price target of $211.86, indicating a potential upside of 98.71%. Mirum Pharmaceuticals has a consensus price target of $139.80, indicating a potential upside of 19.37%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts clearly believe Insmed is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.11	-$1.28B	-$5.75	N/A
Mirum Pharmaceuticals	$521.31M	13.70	-$23.36M	-$13.61	N/A

Mirum Pharmaceuticals has a net margin of -140.24% compared to Insmed's net margin of -144.44%. Mirum Pharmaceuticals' return on equity of -11.28% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Insmed beats Mirum Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

79.9% of Viatris shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Viatris presently has a consensus target price of $17.50, suggesting a potential upside of 10.20%. Mirum Pharmaceuticals has a consensus target price of $139.80, suggesting a potential upside of 19.37%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A
Mirum Pharmaceuticals	$521.31M	13.70	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Viatris' score of 0.54 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris has a net margin of -2.04% compared to Mirum Pharmaceuticals' net margin of -140.24%. Viatris' return on equity of 19.04% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Viatris on 10 of the 17 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.50B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-8.61	20.90	27.51	24.87
Price / Sales	13.70	341.80	540.69	102.84
Price / Cash	2,412.75	143.77	48.53	58.59
Price / Book	19.14	8.75	11.01	6.54
Net Income	-$23.36M	$23.81M	$3.57B	$336.70M
7 Day Performance	2.05%	3.60%	2.31%	2.88%
1 Month Performance	21.58%	3.72%	1.38%	0.64%
1 Year Performance	142.03%	68.80%	36.70%	31.34%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	2.911 of 5 stars	$117.12 -4.8%	$139.80 +19.4%	+130.1%	$7.50B	$521.31M	N/A	140
MRNA Moderna	1.1051 of 5 stars	$60.42 -1.0%	$36.60 -39.4%	+153.8%	$24.20B	$1.94B	N/A	4,700
ROIV Roivant Sciences	2.0251 of 5 stars	$34.01 +5.6%	$33.59 -1.2%	+214.0%	$23.17B	$8.26M	N/A	860	Positive News Insider Trade
BNTX BioNTech	4.1328 of 5 stars	$90.21 -0.5%	$129.56 +43.6%	-12.6%	$22.92B	$3.25B	N/A	7,807	Positive News
INSM Insmed	3.7145 of 5 stars	$103.44 +1.3%	$211.86 +104.8%	+5.9%	$22.14B	$606.42M	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. MRNA, ROIV, BNTX, INSM, and VTRS

How does Mirum Pharmaceuticals compare to Moderna?

Summary

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Summary

How does Mirum Pharmaceuticals compare to Insmed?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. MRNA, ROIV, BNTX, INSM, and VTRS

How does Mirum Pharmaceuticals compare to Moderna?

Does the media favor MIRM or MRNA?

Is MIRM or MRNA more profitable?

Which has preferable valuation & earnings, MIRM or MRNA?

Which has more volatility & risk, MIRM or MRNA?

Do analysts rate MIRM or MRNA?

Do institutionals & insiders hold more shares of MIRM or MRNA?

Summary

How does Mirum Pharmaceuticals compare to Roivant Sciences?

Does the media prefer ROIV or MIRM?

Is ROIV or MIRM more profitable?

Which has preferable earnings & valuation, ROIV or MIRM?

Do analysts rate ROIV or MIRM?

Do insiders and institutionals believe in ROIV or MIRM?

Which has more volatility and risk, ROIV or MIRM?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Which has better earnings and valuation, BNTX or MIRM?

Does the media favor BNTX or MIRM?

Is BNTX or MIRM more profitable?

Do institutionals and insiders believe in BNTX or MIRM?

Which has more risk and volatility, BNTX or MIRM?

Do analysts rate BNTX or MIRM?

Summary

How does Mirum Pharmaceuticals compare to Insmed?

Which has more risk & volatility, INSM or MIRM?

Does the media refer more to INSM or MIRM?

Do analysts recommend INSM or MIRM?

Which has better earnings & valuation, INSM or MIRM?

Is INSM or MIRM more profitable?

Summary

How does Mirum Pharmaceuticals compare to Viatris?

Do insiders and institutionals hold more shares of VTRS or MIRM?

Do analysts prefer VTRS or MIRM?

Which has stronger earnings and valuation, VTRS or MIRM?

Does the media favor VTRS or MIRM?

Is VTRS or MIRM more profitable?

Which has more volatility & risk, VTRS or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools